Pulmonary tuberculosis is an infection of the lungs caused by the bacterium Mycobacterium tuberculosis, and it remains one of the leading infectious-disease killers worldwide. What makes TB unusual is the long, quiet standoff it can wage inside the body: most people who breathe in the bacterium never get sick, yet the organism can linger for years or decades before flaring into active disease. The biology behind that standoff, the tools used to detect it, and the challenges of treating it have all evolved considerably in recent years, and there is more to the story than the classic textbook picture of a persistent cough and a cavitary chest X-ray.
How TB Spreads
TB passes from person to person through the air. When someone with active pulmonary TB coughs, talks, or even just breathes, tiny droplets carrying the bacterium can hang suspended long enough for another person to inhale them. In a study of over 100 people with culture-confirmed TB, roughly a quarter produced culturable bacteria when they coughed, and nearly all of the infectious particles fell in a size range small enough to reach deep into the lungs.1PubMed Central. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis The output varied enormously from person to person, which helps explain why some TB patients infect many close contacts and others infect none.
A common assumption is that coughing is what makes someone with TB contagious. Research has challenged that idea. TB bacteria have been detected in the exhaled breath of patients who did not cough at all during the sampling period. The likely explanation is a mechanism in which thin fluid films lining the small airways burst during normal breathing, flinging bacteria into the air with each breath.2PubMed Central. Is cough really necessary for TB transmission? Coughing makes things worse because it generates more and larger bursts, but it is not strictly required. This matters for infection control: a person who “just has a cough” is not the only transmission risk, and screening programs that rely solely on cough as a trigger can miss contagious individuals.
What Happens Inside the Lungs
Once inhaled, the bacteria settle in the lung tissue, where immune cells called macrophages try to engulf and destroy them. TB has evolved to survive inside those very cells. In response, the immune system walls off the infection by building a structure called a granuloma, a tight cluster of macrophages and other immune cells surrounded by a ring of lymphocytes.3PubMed Central. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria? The granuloma is the hallmark of TB, and it can do one of two things: hold the bacteria in check indefinitely, producing what we call latent TB infection, or break down, releasing bacteria and causing active disease.
The immune signals that maintain this containment involve a coordinated effort. Interferon-gamma activates macrophages and helps them kill intracellular bacteria, while tumor necrosis factor (TNF-alpha) works alongside it, helping recruit immune cells to the infection site and keeping the granuloma intact.4PubMed Central. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis This is why drugs that block TNF-alpha, used for conditions like rheumatoid arthritis and Crohn’s disease, carry a well-known risk of reactivating latent TB. Without that signal, granulomas can fall apart.
The bacterium is not a passive bystander in this immune tug-of-war. Research has shown that M. tuberculosis can reduce the surface expression of the interferon-gamma receptor on immune cells, effectively blunting one of the host’s main weapons. After anti-TB treatment, receptor levels come back up.5PubMed Central. Modulation of gamma interferon receptor 1 by Mycobacterium tuberculosis: a potential immune response evasive mechanism The organism has had a long time to develop such tricks: genomic analyses estimate that the TB complex has been co-evolving with humans for roughly 40,000 to 70,000 years, expanding during periods of population growth.6PubMed Central. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans
Symptoms and Imaging
The classic presentation of active pulmonary TB includes a persistent cough lasting weeks, often with blood-streaked sputum, along with fevers, night sweats, weight loss, and fatigue. But TB can look quite different depending on the person’s immune status and age. In children and people with weakened immune systems, the first episode of TB (called primary TB) tends to show up on chest imaging as swollen lymph nodes and areas of lung consolidation rather than the textbook cavities.7PubMed. Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management
Even in otherwise healthy adolescents and young adults, the imaging is not always straightforward. A study of high school students with TB found that about a third had lesions in atypical locations, primarily in the lower parts of the lungs rather than the upper zones where TB classically lives. Roughly 5% had completely normal chest X-rays despite confirmed disease.8PubMed Central. Chest Radiographic Findings in Primary Pulmonary Tuberculosis: Observations from High School Outbreaks This is a practical reminder that a normal-looking X-ray does not rule out pulmonary TB, and relying on imaging alone will miss cases.
Diagnosing Active TB
For decades, the front-line diagnostic test in many parts of the world has been sputum smear microscopy, in which a lab technician examines a stained sputum sample under a microscope looking for the bacteria. It is cheap and fast, but its sensitivity is poor. One comparative study found that smear microscopy caught only about 22% of culture-confirmed cases.9PubMed Central. Comparative Study of GeneXpert with ZN Stain and Culture in Samples of Suspected Pulmonary Tuberculosis That means it missed nearly four out of five people who actually had TB.
The GeneXpert platform, a rapid molecular test, has substantially improved on this. The same study reported an overall sensitivity around 87% and a specificity above 93% for GeneXpert, and it also identified positive results in samples that microscopy had called negative.10PubMed Central. Comparison of microscopic and xpert MTB diagnoses of presumptive mycobacteria tuberculosis infection Beyond detecting the bacterium, GeneXpert simultaneously checks for resistance to rifampicin, one of the most important TB drugs, giving clinicians critical information within a couple of hours rather than the weeks required by traditional culture.
Testing for Latent TB
Latent TB is a different diagnostic challenge. People with latent infection feel fine and are not contagious, but they carry a risk of progressing to active disease later. Two main testing approaches exist: the tuberculin skin test (TST), which involves injecting a small amount of protein under the skin and reading the reaction two to three days later, and blood-based interferon-gamma release assays (IGRAs), which measure the immune response to TB-specific proteins in a lab.
Both tests are good at detecting latent infection, but IGRAs have an edge in people who received the BCG vaccine, particularly if they were vaccinated after infancy. The skin test can cross-react with BCG, producing false positives, while IGRAs are more specific.11PubMed Central. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence When it comes to predicting who will actually progress from latent to active TB, though, both tests are limited. A recent meta-analysis found that IGRAs had a somewhat higher predictive value than the skin test, but even the IGRA’s positive predictive value was only about 2.5%, meaning that the vast majority of people who test positive will never develop active disease.12PubMed. Predictive value of interferon-gamma release assays and tuberculin skin test for latent tuberculosis infection: A systematic review and meta-analysis of head-to-head comparative tests That low predictive value is one reason clinicians weigh risk factors like HIV status and recent exposure alongside the test result, rather than treating every positive test automatically.
Standard Treatment
Treating drug-susceptible pulmonary TB typically takes six months or more and involves a combination of antibiotics. The backbone of therapy remains isoniazid, rifampicin, and pyrazinamide, usually with ethambutol added during the first two months until drug-susceptibility results come back.13PubMed Central. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances The reason for the long duration and multiple drugs is the bacterium’s ability to enter a slow-growing or dormant state inside granulomas, where single agents struggle to reach and kill it.
Research into why some bacteria survive treatment despite not being genetically resistant has pointed to so-called persister cells. These are bacteria that switch into a tolerant metabolic state. Studies have found that certain TB mutants produce higher fractions of these persisters, and their tolerance extends across multiple drug classes regardless of antibiotic concentration or growth conditions.14PubMed Central. High Persister Mutants in Mycobacterium tuberculosis The metabolic trick behind this may involve shifts in how the bacterium processes trehalose, an internal sugar. Rather than using trehalose to build cell-surface structures, persister-like bacteria reroute it to fuel core energy production and antioxidant defenses, helping them weather antibiotic exposure.15Nature Communications. Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis Understanding these survival strategies is important because they represent potential targets for new drugs or adjunctive therapies that could shorten treatment.
Drug Resistance
When TB bacteria acquire genetic mutations that make them resistant to the two most powerful first-line drugs, isoniazid and rifampicin, the result is multidrug-resistant TB (MDR-TB). Treatment for MDR-TB is longer, more expensive, and uses drugs with harsher side effects. Resistance in TB arises from spontaneous chromosomal mutations rather than the transfer of resistance genes between bacteria, which means every mechanism of resistance is specific to the drug in question.16PubMed Central. Drug Resistance Mechanisms in Mycobacterium tuberculosis
Newer drugs have offered some relief. Bedaquiline and clofazimine have become key components of MDR-TB regimens. However, resistance to these newer agents can emerge through a shared pathway: mutations in a gene called rv0678, which controls a drug efflux pump. When that pump is upregulated, the bacterium can push both bedaquiline and clofazimine out of the cell. In laboratory studies, this single mutation accounted for the overwhelming majority of resistant strains.17Journal of Antimicrobial Chemotherapy. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline The cross-resistance between these two drugs is a concern for treatment programs, because losing both at once significantly narrows options.
TB and HIV
HIV is the single most powerful driver of TB reactivation. People living with both infections face a complex clinical picture: HIV complicates every stage of TB, from diagnosis (because weakened immunity can produce atypical symptoms and negative sputum smears) to treatment (because TB drugs and antiretroviral drugs interact, pile on side effects, and sometimes trigger a paradoxical worsening called immune reconstitution inflammatory syndrome, or IRIS, when the recovering immune system overreacts to TB remnants).18PubMed Central. Diagnosis & treatment of tuberculosis in HIV co-infected patients
The mechanism behind HIV-driven reactivation is more complex than simple CD4 cell loss. Primate studies found that depleting CD4 cells alone, without actual viral infection, was not enough to reactivate latent TB. Instead, the chronic immune activation and disrupted T-cell balance caused by the virus itself appear to be key drivers.19JCI Insight. Mechanisms of reactivation of latent tuberculosis infection due to SIV coinfection A further complication specific to co-infected patients is acquired rifampicin resistance, which can develop when intermittent TB regimens are used without timely initiation of antiretroviral therapy.20PubMed. TB-HIV co-infection: a catastrophic comradeship Current guidelines therefore emphasize starting antiretroviral therapy as early as possible alongside TB treatment.
TB in Children
Diagnosing pulmonary TB in children is especially difficult. Young children rarely produce sputum on their own, and even when samples are obtained through gastric aspirate (collecting stomach contents that include swallowed respiratory secretions), the yield is modest. A study of pediatric TB patients found that a single gastric aspirate had a sensitivity of only about 34%, and collecting three on consecutive mornings raised that to roughly 47%.21PubMed Central. Does multiple gastric aspirate collection increase sensitivity of M. tuberculosis detection in children with pulmonary tuberculosis? The improvement was most pronounced in children under four and in those with uncomplicated disease.
When bronchoalveolar lavage (a more invasive procedure) was compared head-to-head with gastric aspirate and nasopharyngeal aspirate in children, the lavage fluid consistently gave the highest culture-positive rates, while nasopharyngeal samples performed the worst.22The Turkish Journal of Pediatrics. The value of nasopharyngeal aspirate, gastric aspirate and bronchoalveolar lavage fluid in the diagnosis of childhood tuberculosis In practice, many pediatric TB cases are diagnosed clinically, based on a combination of a known TB contact, a positive skin test or IGRA, suggestive imaging, and response to treatment, rather than a confirmed culture. This makes childhood TB one of the most underdiagnosed forms of the disease.
Life After TB
Completing treatment and clearing the infection does not mean the lungs bounce back to normal. More than half of people who are microbiologically cured of TB are left with measurable lung damage, a condition increasingly recognized as post-TB lung disease.23PubMed Central. Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances Impaired lung function after treatment adds to the global burden of chronic respiratory illness, and for many survivors, it means lasting breathlessness, reduced exercise tolerance, and an increased risk of future respiratory infections.24PubMed Central. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium This is an area where research is catching up with clinical reality. For decades, TB programs focused almost exclusively on cure; the long-term respiratory health of survivors received far less attention.
Risk Factors Beyond the Bacterium
Whether someone exposed to TB actually develops disease depends on a web of factors. Crowded living conditions, poor ventilation, and indoor air pollution from biomass fuels all increase risk. A study in Pakistan found that adult crowding, poor ventilation, and use of biofuels were among the strongest environmental predictors of pulmonary TB.25Epidemiology. Environmental Risk Factors and Social Determinants of Pulmonary Tuberculosis in Pakistan Housing affordability, which drives overcrowding and substandard living conditions, may matter even more than the physical quality of the home itself.26PubMed Central. Inadequate housing and pulmonary tuberculosis: a systematic review
Genetics also plays a role. Variations in the vitamin D receptor gene have been linked to susceptibility in multiple populations. In an Indonesian study, certain genotypes roughly doubled the odds of developing pulmonary TB compared to controls.27PubMed Central. Vitamin D receptor gene variations and tuberculosis susceptibility: Insights from Indonesian populations Studies in Indian populations found similar patterns, with specific vitamin D receptor variants associated not just with TB susceptibility but with more severe outcomes like higher bacterial loads and multidrug resistance.28PubMed. Coding and non-coding polymorphisms in VDR gene and susceptibility to pulmonary tuberculosis in tribes, castes and Muslims of Central India Vitamin D helps macrophages generate antimicrobial molecules, so genetic differences in how the body responds to vitamin D may have real functional consequences for TB defense. That said, these genetic associations represent one piece of a much larger puzzle that includes nutrition, smoking, diabetes, and immune-suppressing medications.
BCG and the Search for Better Vaccines
The BCG vaccine, derived from a weakened strain of a related bovine tuberculosis bacterium, has been in use since 1921. It is effective at preventing severe forms of TB in children, such as TB meningitis, and evidence supports its efficacy against adult pulmonary TB as well.29PubMed. A Breath of Fresh Air: BCG Prevents Adult Pulmonary Tuberculosis The problem is that its protection against pulmonary disease in adults varies widely across populations and geographic regions, for reasons that are still debated after a century of use.30PubMed Central. Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
Several next-generation vaccine candidates are in development, including whole-cell vaccines like MTBVAC (a live attenuated strain of M. tuberculosis itself) and protein-based subunit vaccines. Preclinical trials have shown improved immune responses and better protection compared to BCG for some of these candidates.31Jurnal Biologi Tropis. Article Review: Development of a new type of TB vaccine as a replacement for the BCG vaccine The M72/AS01E subunit vaccine, for instance, showed roughly 50% efficacy against active pulmonary TB disease in a large clinical trial of adults with latent infection, a result that generated considerable excitement in the field. Whether any of these candidates will eventually replace or supplement BCG remains to be seen, but the pipeline is more active now than at any point in decades.
AI-Assisted Screening on Chest X-Rays
One of the practical bottlenecks in TB control is reading chest X-rays at scale, especially in settings where trained radiologists are scarce. Artificial intelligence software that can flag X-rays suggestive of TB has emerged as a screening tool. A systematic review and meta-analysis concluded that AI software demonstrates strong diagnostic performance for detecting TB on chest X-rays and can help clinicians make faster, more accurate screening decisions.32PubMed Central. A systematic review and meta-analysis of artificial intelligence software for tuberculosis diagnosis using chest X-ray imaging
Not all products perform equally. A head-to-head evaluation of 12 commercial AI tools in South Africa found that the top performers achieved areas under the curve above 0.86, with two products statistically outperforming the rest.33The Lancet Digital Health. Evaluation of 12 commercial artificial intelligence software products for estimating tuberculosis prevalence and screening in South Africa: a cross-sectional study In a separate multicenter migrant-screening study, the best-performing AI system achieved sensitivity comparable to that of expert radiologists.34PLOS Global Public Health. Diagnostic accuracy of three computer-aided detection systems for detecting pulmonary tuberculosis on chest radiography when used for screening These tools are not intended to replace confirmatory microbiological testing, but they can serve as a triage step: flagging suspicious X-rays so that molecular testing like GeneXpert can be directed to the people most likely to need it.
The Gut-Lung Axis in TB
An emerging area of research looks at how the communities of microorganisms living in the gut and lungs influence TB. The idea of a “gut-lung axis” is based on evidence that the microbes colonizing both sites help regulate regional immune responses, and that disruptions to those microbial communities can affect how the body handles TB. Research suggests that changes in the gut and lung microbiome occur across the entire spectrum of TB, from initial infection through active disease, treatment, and recovery.35PubMed Central. The gut and lung microbiome across the TB disease spectrum
Anti-TB therapy itself reshapes the microbiome, which may in turn affect treatment outcomes and the risk of relapse.36PubMed Central. Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential The six-month course of broad-spectrum antibiotics that forms the backbone of TB treatment does not selectively kill TB alone; it inevitably disrupts gut and respiratory bacteria. Whether supporting or restoring the microbiome during treatment could improve cure rates or reduce post-treatment complications is still an open question, but it represents one of the more intriguing directions in TB research. In a disease where the standard drug regimen has barely changed in decades, understanding the wider biological context of infection and recovery could eventually open up new therapeutic angles.